Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneDx HoldingsWGS +5.26%66 3-Year Book Growth Rate is -21.20% as of Jun. 2026. GuruFocus rates WGS with a GF Score™ of 66/100 and a GF Value™ of $74.09 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, GeneDx Holdings ranks worse than 78.01% on this metric.
During the past 12 months, GeneDx Holdings's average Book Value per Share Growth Rate was -15.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -21.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of GeneDx Holdings was -21.20% per year. The lowest was -45.10% per year. And the median was -33.15% per year.
GeneDx Holdings (NAS:WGS) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
GeneDx Holdings 3-Year Book Growth Rate Related Terms
WGS vs CDNA, NEO, PSNL: 3-Year Book Growth Rate Comparison
For the Diagnostics & Research subindustry, GeneDx Holdings's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneDx Holdings 3-Year Book Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where GeneDx Holdings's 3-Year Book Growth Rate falls into.
GeneDx Holdings 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -21.20% mean?
GeneDx Holdings (WGS) has a 3-Year Book Growth Rate of -21.20% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for GeneDx Holdings and its competitors. According to the industry distribution chart, GeneDx Holdings ranks #149 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 78%.
Is GeneDx Holdings' 3-Year Book Growth Rate too high?
GeneDx Holdings' current 3-Year Book Growth Rate is -21.20%. Based on the distribution chart, GeneDx Holdings ranks #149 out of 191 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, GeneDx Holdings has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' 3-Year Book Growth Rate compare to CDNA and NEO?
According to the Medical Diagnostics & Research industry distribution chart, GeneDx Holdings ranks #149 out of 191 companies for 3-Year Book Growth Rate. This places GeneDx Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Diagnostics & Research company?
A good 3-Year Book Growth Rate depends on the Medical Diagnostics & Research industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for GeneDx Holdings and its competitors. GeneDx Holdings's current 3-Year Book Growth Rate is -21.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $74.09, compared to a current price of $89.74 — trading 21.1% above its estimated fair value. The current 3-Year Book Growth Rate is -21.20%. GeneDx Holdings' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current 3-Year Book Growth Rate is -21.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneDx Holdings (WGS) Overvalued in 2026?
Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued.
The current stock price of $89.74 is trading 21.1% above its estimated GF Value™ of $74.09.
GuruFocus considers GeneDx Holdings to be Modestly Overvalued.
Key valuation signals for WGS:
3-Year Book Growth Rate: -21.20%
GF Value™: $74.09 vs. price of $89.74 (21.1% above fair value)
No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
66GF Score
Get the complete analysis for WGS
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WGS has been successfully added to your 
